Business · 1 sources covering this

Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why

Goldman Sachs retained its Buy rating on Cohance Lifesciences with a target price of Rs 525, while cutting its fiscal 2027–29 earnings estimates by up to 31%.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·2h ago
Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why
Goldman Sachs retained its Buy rating on Cohance Lifesciences with a target price of Rs 525, while cutting its fiscal 2027–29 earnings estimates by up to 31%.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/978bb2af0a92b65d8c4b6d655512b91216573f98"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why"></iframe>

Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why

How 1 sources are covering this

Cohance Lifesciences Q2 Review: Brokerages Maintain Mixed Views | Here's Why

More from Business

Fermin stars as Barcelona come from behind to defeat Atletico Madrid 2-1

Bank holiday today: Are banks open or closed on November 9? Check details

Man United stage late comeback to hold Aston Villa 4-4 at Old Trafford

Rupee extends winning streak, breaks below 94 against dollar: What's next

Reader

Trust & legal

Across the network